July reorganization of sales and marketing organization places Alan Milbauer, former VP-planning, as VP-marketing. Milbauer replaces Andrew Kay, who is now primary care marketing head at ICI's U.K. headquarters. Four new marketing directors in charge of different therapeutic areas will report to Milbauer: Christopher Iacono (anesthesia/pulmonary/arthritis), Thomas Lyons (anti- infectives/CNS/metabolism), Bradford Patten (oncology/endocrine) and Edward Seage (cardiovascular). Former VP-Sales Timothy Flood given the new title of VP-Market Development.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth